Clinical and preclinical data demonstrate that altered pulmonary physiology (including increased inflammation, increased blood flow, airway resistance, and hyper-reactivity) is an intrinsic component of Sickle Cell Disease (SCD) and may contribute to excess SCD morbidity and mortality.
The lung plays an essential role in SCD pathophysiology as it is the only organ that reverses red cell sickling, which occurs during hemoglobin deoxygenation. A growing body of clinical and preclinical data demonstrates that altered pulmonary physiology (including increased inflammation, increased blood flow, airway resistance, and hyperreactivity) is an intrinsic component of SCD and may contribute to excess SCD morbidity and mortality. [2] [3] [4] [5] [6] Therapies to ameliorate the altered pulmonary physiologic milieu in SCD are a promising avenue for disease modification.
Comorbid asthma is a well-established risk factor for increased SCD morbidity and mortality, and more recent observational research identified high rates of airway hyperreactivity, obstruction, and wheezing in individuals with SCD who do not have asthma. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Several studies demonstrated a link between the presence of respiratory symptoms and SCD complications including pain, acute chest syndrome, and death. 9, [17] [18] [19] In one prospective cohort of nonasthmatic individuals with SCD, the rate of pain episodes doubled during 8-week periods after self-reported cough or wheeze (mostly in the setting of upper respiratory infection as patients with asthma were excluded) and there was a trend towards increased rates of acute chest syndrome. 13 These data and other observational studies suggested a temporal link between respiratory symptoms and SCD pain, raising the question of whether therapies aimed at reversing airway obstruction and inflammation could benefit nonasthmatic individuals with SCD, particularly after periods of self-reported wheeze or cough.
The etiology of nonasthmatic lung function abnormalities in SCD is an area of ongoing investigation. Sickle mice demonstrate elevated airway inflammation, higher levels of pulmonary CD41 and CD81 T cells and myeloid activation chemokines. 6, 20, 21 This inflammation does not appear to be driven exclusively by eosinophilic processes in humans as levels of exhaled nitric oxide (eNO) are only slightly higher in SCD compared with healthy controls but not as high as individuals with poorly controlled asthma. 22, 23 Given these data, anti-inflammatory asthma therapies (oral leukotriene inhibitors 24 and inhaled corticosteroids) are promising as adjuvant SCD therapy. Emerging data suggest that elevated pulmonary capillary blood volume and flow (resulting from chronic anemia) are important contributors to the observed increase in airway resistance in SCD 25 and therefore therapies (such as hydroxyurea and transfusion) aimed at ameliorating the high flow state may have greater benefit than bronchodilators. While hydroxyurea is associated with improvements in lung function, transfusion resulted in further increases in pulmonary capillary blood volume and airway resistance. 26 With this study, we aimed to evaluate the efficacy and feasibility of inhaled corticosteroids (ICS) for individuals with SCD who do not have asthma.
| M E T H O D S

| Study design and conduct
With this single-site, randomized, placebo-controlled, triple-blind phase II trial, we tested the hypothesis that in nonasthmatic individuals with SCD who report recent cough or wheeze, ICS administered for a 16-week period will reduce SCD-related complications, improve patientreported outcomes and reduce biological markers of pulmonary inflammation and vascular injury in comparison to placebo. We also tested protocol fidelity and feasibility in preparation for a future multisite trial.
The single primary endpoint for the trial was feasibility (defined as the number of participants who meet criteria for per-protocol analysis of all clinical and biologic outcomes divided by the total number enrolled)
however we did specify a priori patient-reported (daily pain diary scores over time) and biologic outcomes (change in sVCAM and change in eNO between zero and eight weeks). To meet criteria for perprotocol analyses, participants were required to maintain at least 70% adherence to study medication, complete the 8-week (1/-2 weeks) assessment of biological outcomes (spirometry, blood draw, and questionnaires), and fill out at least 30 pain diaries. The intent-to-treat analysis included all participants except those who were lost to follow-up prior to the first data collection point (two individuals were lost, and had no data for analysis). The target sample size was 45 participants with a 2:1 allocation to drug vs. placebo. A sample size calculation was performed for the a priori patient-reported outcome of daily pain diary scores. To detect a difference in mean pain score of 1 point for ICS vs. Each participant provided written informed consent. A complete schedule of protocol changes is included in the supplement. Protocol changes were minor and had no effect on the intervention, study outcomes or the intent to treat analyses.
| Patients
Eligibility criteria for the study were HbSS or HbSb0 thalassemia (confirmed by electrophoresis), age 15 or older and a patient self-report of cough or wheeze over the preceding two months. Exclusion criteria included a diagnosis of asthma, incarceration, pregnancy, more than 15
ED visits for SCD pain over the prior 12 months and discharge from the hospital within the previous 7 days. Specifically, patients with asthma were excluded because it was not considered ethical to randomize patients with asthma and wheezing to placebo. A multistep algorithm with high sensitivity in adults and children 13, 27 was used to identify and exclude all individuals with asthma or possible asthma and is included as a supplement. Briefly, any individual who carried a diagnosis of asthma or a history of using asthma medications was excluded.
For individuals with no asthma diagnosis, they were excluded if they had any three of the following criteria: (1) Wheeze causing shortness of breath, (2) wheeze without colds, (3) wheeze with exercise, and (4) family history of asthma in a parent. All data were collected at the Mount Sinai Medical Center (inpatient, ED, ambulatory clinics) or via telephone.
| Study therapy and adaptive randomization
Participants were randomized in a 2:1 fashion to receive once-daily inhaled mometasone furoate 220 mcg twisthaler or placebo for 16 weeks in addition to standard SCD care. The 2:1 allocation ratio was chosen to (1) demonstrate the feasibility of unequal allocation schema if necessary in future trials and (2) to generate safety data for mometasone (by exposing more patients to active drug). Participants were observed for an additional 4-week washout period after study completion (up to 20 weeks) however if patients felt marked symptom improvement they were allowed to continue the study medication (instead of washing out) at the discretion of their healthcare provider.
To ensure equal allocation of patients on hydroxyurea and equal allocation of patients with low, medium, and high rates of ED utilization, a covariate-balancing, adaptive, biased-coin randomization algorithm was employed. 28 Briefly, the adaptive, biased-coin changed the probability of treatment assignment based on the degree of existing imbalance between groups (with respect to hydroxyurea use and prior rate of ED utilization) for participants already in the trial. Unlike a stratified block randomization, the biased coin algorithm altered probability (between 10% and 90%) but never made deterministic assignments to maintain balance. This approach was chosen because it made masking of treatment assignment more feasible but maintained a similar degree of covariate balance to traditional stratified block randomization. Randomization assignments were performed by a separate, unblinded research coordinator who was not responsible for data collection or assessment.
Participants, physicians, investigators, and data collectors were all blinded to treatment assignment.
| Measures to improve adherence and reduce attrition
Adherence was assessed with dose counters on mometasone twisthalers (placebo inhalers did not have dose counters and had a different appearance than mometasone inhalers-detailed description of procedures to maintain complete blinding of patients, providers, data collectors, and analyzers are available in the supplement) and self-reported adherence via follow-up phone calls for placebo. In addition, the medication adherence report scale for asthma (a 10 question tool scored between 0 and 5 with higher scores indicating greater adherence) 29, 30 was administered to all patients to evaluate its utility in measuring inhaler adherence in people with SCD. To improve adherence, a training module was adapted from the National Asthma Education and Prevention Program and the NIH Breathe Easier module. 31 The module included training and education on proper use of ICS, medication side effects and mechanism of action (in lay-person terms), inhaler technique and a 10-min structured coaching session to improve medication adherence (see Supporting Information).
| Efficacy and safety assessments
Participants were assessed in-person at trial entry, at 8-weeks and at 16-weeks (study completion). At study entry and 8-weeks, assessments There were no a priori safety or futility parameters for the study. There were no serious adverse events at the interim analysis and the study was allowed to continue to completion.
| Serum quantification of cytokines
Blood for serum was collected in Vacutainer serum separator tubes (BD, Franklin Lakes, NJ, USA). Tubes were stored cold for less than 6 h until centrifugation. Serum was separated and stored at 2808C until analysis. All cytokines were analyzed by a bead-based ELISA method (R&D Systems, Minneapolis, MN) using a Luminex 200 (Luminex Corporation, Austin, TX, USA). All samples were run in duplicate, and both visits of each subject were analyzed simultaneously on the same plate, eliminating any variability between assays.
| Statistical analyses
All statistical analyses were performed using SAS version 9. Table 1 . At study entry, participants in the placebo group were older than the mometasone group (mean 36 vs. 30 years, P 5 0.02). There were no other statistically significant differences in baseline characteristics between treatment groups nor were there statistically significant associations between covariates (age, gender, baseline laboratory values) and outcome variables. Rates of obstructive lung disease were low in both groups and there were no cases of response to bronchodilator during spirometry. ENO levels were normal in both groups at baseline.
| Inhaled corticosteroids reduce patient-reported pain
For the outcome of pain score over time, the adjusted treatment effect of mometasone was a reduction in daily pain score of 1.42 points (95%CI 0.61-2.21, P 5 0.001). Figure 2 shows pain scores by week stratified by treatment group. between groups. There were no significant differences between groups with respect to changes in spirometry over time.
| Safety, adherence, and attrition
There were no deaths, cases of pneumonia or acute chest syndrome during the study period. Rates of nonserious adverse events including hoarseness of voice, thrush and sore throat were numerically higher for the mometasone group but were not statistically significant ( Table   3 ). The rate of overall medication adherence was 92.6% for the placebo group and 84.7% in the mometasone group (mean difference 7.9%, 95% CI 21.35 to 17.14, P 5 0.09). Individuals in the mometasone group had a significantly lower average score on the medication adher- discrimination was a score of 4.5 out of 5 which had 47% sensitivity and 100% specificity for identification of medication adherence.
With respect to trial attrition, there were 2 patients lost to followup prior to collection of any outcome data at 1 (placebo) and 4 (mometasone) weeks (one dropped out of the trial after one week, the other 
| DISCUSSION
Here we report results of a single center, randomized, placebo-controlled, triple-blinded feasibility study of ICS for nonasthmatic individuals with SCD. While the primary goals of the study were to demonstrate protocol fidelity and feasibility, there was also a statistically significant benefit with respect to the a priori clinical outcome: daily pain diary score. Prior studies have found a minimum clinically significant difference between two pain scores to be 1.3 points on a 0-10 scale for acute pain 33 and participants in the current study experienced a mean daily improvement in pain score of 1.42 points over four months. With multiple measurements (as were done in this study), the minimum clinically important difference has been shown to decrease further. 34 The findings reported herein provide an initial indication that ICS may be a useful adjuvant therapy for nonasthmatic individuals with SCD.
In addition to the main clinical outcome of pain diary scores, the trial also showed a statistically significant benefit for ICS with respect to change in sVCAM. This cytokine was chosen as the primary marker of vascular injury for because higher sVCAM levels are correlated with increased SCD morbidity and mortality. [35] [36] [37] [38] [39] It was also chosen because sVCAM was measured in peripheral blood away from the site of action of the drug (the lung) and the dose of inhaled mometasone used in this trial does not achieve detectable levels in the blood. Reticulocyte percent, a clinical marker of hemolytic burden, also showed a statistically significant benefit for ICS and a similar, nonsignificant result was seen with serum LDH and absolute reticulocyte count. These biological assays worsened for the placebo group during the trial. may not be a marker of steroid responsive eosinophilic inflammation.
The lack of difference between groups with spirometry was likely because individuals with asthma were screened out and most had normal spirometry at entry. Another important strength of the study is that there was no observed increase in the rate of pulmonary infections or serious adverse events which provides important preliminary safety data for ICS in SCD. found higher specificity (100% vs 69.4% previously) and lower sensitivity (47% vs. 82.4% previously). 29, 30 As with previous studies of the medication adherence report scale, a cutoff of 4.5 had the greatest discriminatory value. The National Asthma Education and Prevention
Program has a number of carefully constructed tools to improve adherence to asthma controller medication and this trial used an adapted version of these materials. These adapted tools were easy to administer and may be useful for future studies of ICS in SCD and for clinical use of ICS in SCD. 
